Browsing Tag

schizophrenia

AbbVie tumbles after new schizophrenia drug fails two trials

(Bloomberg) -- AbbVie Inc. shares fell. (ABBV) fell by the most in three years after two mid-stage trials of its schizophrenia drug failed to meet their primary target, a blow to the company's $8.7 billion acquisition of Cerevel…

Teva schizophrenia drug Phase III results excite analysts

Investor Empires

Teva Pharmaceutical Industries Limited (New York Stock Exchange: Tifa; level: Tifa) saw its share price rise by 12.8% yesterday, amid high trading volume, to its highest level in five years. The stock price of $15.74…

Bristol Myers schizophrenia therapy safe in late-stage trial

Investor Empires

hapabapa/iStock Editorial via Getty Images Bristol Myers Squibb (NYSE:BMY) announced Saturday that its experimental schizophrenia therapy KarXT, acquired as part of its recent Karuna Therapeutics buyout, indicated a well-tolerated…

FDA approves innovative Teva schizophrenia drug

Investor Empires

Teva Pharmaceutical Industries Limited (New York Stock Exchange: teva; level: teva) and MedinCell (Euronext: MEDCL) have announced that the US Food and Drug Administration (FDA) has approved UZEDY (risperidone)…